-- AB Science, Enel, France Telecom, Roche: European Equity Preview
-- B y   L u   W a n g
-- 2010-12-17T05:00:00Z
-- http://www.bloomberg.com/news/2010-12-16/ab-science-enel-roche-telefonica-european-equity-preview.html
The following companies’ shares may
have unusual moves in  European  trading. Stock symbols are in
parentheses, and prices are from the previous close.  The  Stoxx Europe 600 Index  climbed 0.4 percent to 277.59.
The  Stoxx 50 Index  added 0.4 percent to 2,623.36. The  Euro Stoxx
50 Index , a benchmark for nations using the euro, increased 0.1
percent to 2,845.78.  AB Science SA  (AB FP): The biopharmaceutical company won
approval from the U.S. Food and Drug Administration to sell its
Masitinib treatment in the U.S. to treat mast cell tumors in
dogs. The shares fell 5.3 percent to 7.20 euros.  Aeroports de Paris SA  (ADP FP): The Paris airport operator
said November passenger traffic increased 3.5 percent. The
shares rose 1.8 percent to 60.64 euros.  Enel SpA  (ENEL IM): Italy’s biggest utility had its credit
ratings placed on review for a possible downgrade, Moody’s
Investors Service said. Enel shares gained 0.1 percent to 3.79
euros.  France Telecom SA  (FTE FP): The French telecommunications
services provider was raised to “buy” from “neutral” by
Nomura Holding Inc. The shares rose 0.4 percent to 16.04 euros.  Nomura cut  Telefonica SA  (TEF SM), Spain’s largest phone
company, to “neutral” from “buy.” The stock rose 0.2 percent
to 17.25 euros.  Iberia Lineas Aereas de Espana SA  (IBLA SM): Spain’s
biggest airline said passenger traffic rose 7.9 percent in
November from a year earlier. The load factor, or proportion of
seats filled, fell to 77.4 percent from 77.8 percent. The shares
slipped 0.5 percent to 3.22 euros.  Heurtey Petrochem SA  (ALHPC FP): The maker of refining
equipment said it won a 12.2 million-euro order in India. The
shares fell 0.9 percent to 25.25 euros.  Red Electrica de Espana SA  (REE SM): The manager of Spain’s
power grid said it will pay next month an interim dividend of 59
euro cents per share, 15 percent more than a year earlier. The
shares rose 0.5 percent to 36.07 euros.  Roche Holding AG  (ROG VX): The Swiss company’s top-selling
drug Avastin should no longer be used to treat breast cancer
after recent studies failed to show a benefit, U.S. regulators
said. Separately, the European Medicines Agency said the safety
of the growth hormone somatropin, the key ingredient in
medicines made by Pfizer Inc. and Roche, will be reviewed to see
whether the drugs are too risky. The shares dropped 0.9 percent
to 140 francs.  To contact the reporter on this story:
 Lu Wang  in New York at   lwang8@bloomberg.net   To contact the editor responsible for this story:
Nick Baker at   nbaker7@bloomberg.net . 